首页> 外文期刊>Regulatory Toxicology and Pharmacology: RTP >28-Day repeated dose oral toxicity of recombinant human apo-lactoferrin or recombinant human lysozyme in rats.
【24h】

28-Day repeated dose oral toxicity of recombinant human apo-lactoferrin or recombinant human lysozyme in rats.

机译:重组人载脂乳铁蛋白或重组人溶菌酶对大鼠的28天重复剂量口服毒性。

获取原文
获取原文并翻译 | 示例
           

摘要

Lactoferrin and lysozyme are important proteins of the human innate immune system. These proteins are found in breast milk and have been associated with improved infant health. Recombinant human apo-lactoferrin (apo-rhLF), 1800 and 180mg/kg bw/day, and recombinant human lysozyme (rhLZ), 360 and 36mg/kg bw/day, were orally administered to Wistar rats for 28 days. Apo-rhLF and rhLZ were expressed in rice grain, extracted, purified; the lactoferrin was iron desaturated. The animals were examined for evidence of toxicity; there were no deaths and in-life physical signs were normal. Transient differences in mean food consumption occurred in high dose apo-rhLF and low dose LZ females at week three. There were no biologically significant differences in hematological or clinical chemistry parameters. Necropsy results were normal and microscopic evaluation showed no treatment related changes in animals dosed with 1800mg/kg/day apo-rhLF or 360mg/kg/day rhLZ. The results of the 28-day oral administration demonstrate a lack of toxicity of apo-rhLF and rhLZ in rats. There were no treatment related, toxicologically relevant changes in clinical signs, growth, food consumption, hematology, clinical chemistry, organ weight and pathology. The no observed adverse effect level (NOAEL) is greater than 1800mg/kg/day for apo-rhLF and 360mg/kg/day for rhLZ.
机译:乳铁蛋白和溶菌酶是人类先天免疫系统的重要蛋白质。这些蛋白质存在于母乳中,与改善婴儿健康有关。向Wistar大鼠口服给予1800和180 mg / kg bw /天的重组人载脂乳铁蛋白(apo-rhLF)和重组人溶菌酶(rhLZ)360和36mg / kg bw /天。 Apo-rhLF和rhLZ在水稻籽粒中表达,提取,纯化;乳铁蛋白被铁去饱和。检查动物的毒性证据。没有死亡,生命体征正常。在第三周,高剂量apo-rhLF和低剂量LZ雌性的平均食物消耗存在暂时差异。血液学或临床化学参数在生物学上无显着差异。尸检结果是正常的,并且显微镜评估显示,在剂量为1800mg / kg /天的apo-rhLF或360mg / kg /天的rhLZ的动物中,与治疗无关的变化。口服28天的结果表明apo-rhLF和rhLZ在大鼠中没有毒性。在临床体征,生长,食物消耗,血液学,临床化学,器官重量和病理学方面,没有与治疗有关的,与毒理学相关的变化。对于apo-rhLF,未观察到的不良反应水平(NOAEL)大于1800mg / kg /天,对于rhLZ,未观察到的不良反应水平大于360mg / kg /天。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号